Jazz Pharmaceuticals delivered a strong Q4 2025 with total revenues reaching $1.2 billion, a 10% year-over-year increase. The company achieved record annual revenues of $4.3 billion, driven by growth in Xywav and Epidiolex. Despite a GAAP net loss for the full year due to acquisition-related charges, the company maintained strong cash flow and is preparing for significant product launches in 2026.

Jazz Pharmaceuticals announced its second quarter 2025 financial results, with total revenues reaching $1.05 billion, a 2% increase year-over-year. Despite revenue growth, the company reported a GAAP net loss of $718.5 million, primarily driven by a $905.4 million acquired in-process research and development (IPR&D) expense related to the Chimerix Acquisition. Xywav sales saw a strong 13% increase, while Zepzelca and Rylaze sales decreased. The company updated its full-year 2025 financial guidance.

Revenue remained flat year-over-year at $898 million, with strong growth in Xywav and Epidiolex offset by declines in oncology products and litigation expenses impacting profitability.

Jazz Pharmaceuticals delivered strong financial results in Q4 2024 with record revenue of $1.1 billion, driven by growth in key products like Xywav and Epidiolex. The company's net income and non-GAAP adjusted EPS increased significantly compared to the previous year.

Jazz Pharmaceuticals announced strong Q3 2024 results with record revenues exceeding $1.05 billion. Key growth drivers, including Xywav, Epidiolex, and Rylaze, saw a combined 14% year-over-year revenue increase. The company has affirmed its 2024 total revenue guidance between $4.0 to $4.1 billion.

Jazz Pharmaceuticals announced strong Q2 2024 results with total revenues of over $1 billion, driven by Xywav, Epidiolex and Rylaze. The company is narrowing its 2024 total revenue guidance to $4.0 to $4.1 billion and affirming GAAP and non-GAAP adjusted net income guidance.

Jazz Pharmaceuticals reported a 1% increase in total revenues for Q1 2024 compared to the same period in 2023, driven by a 13% increase in Oncology product sales. Key growth drivers, including Xywav, Epidiolex and Rylaze, delivered combined double-digit year-over-year growth.

Jazz Pharmaceuticals reported a strong Q4 2023, achieving its first $1 billion revenue quarter, driven by key growth drivers like Xywav, Epidiolex, and Rylaze. The company's oncology revenue surpassed $1 billion in 2023, and they anticipate multiple late-stage pipeline catalysts in 2024.

Jazz Pharmaceuticals announced strong financial results for the third quarter of 2023, with total revenues of $972 million and GAAP net income of $146.8 million. The company raised its total revenue and Oncology revenue guidance for the year.

Jazz Pharmaceuticals announced strong second-quarter 2023 financial results, with total revenues of $957 million. The company saw significant demand for Xywav, Epidiolex, and Rylaze, and raised its full-year 2023 financial guidance. They are resuming share repurchases under their existing program.

Jazz Pharmaceuticals announced strong Q1 2023 results with a 10% increase in total revenues to $892.8 million, driven by key products such as Xywav, Epidiolex, and Rylaze. The company is confident in the blockbuster potential of Epidiolex and is on track to achieve full-year revenue expectations.

Jazz Pharmaceuticals reported Q4 2022 total revenues of $972.123 million. The company's Xywav became the largest product by net sales. The company is positioned for total revenue and net income growth in 2023.

Jazz Pharmaceuticals announced strong Q3 2022 results, driven by growth in key products like Xywav and Epidiolex, and raised the mid-point of 2022 total revenue guidance to $3.65 billion.

Jazz Pharmaceuticals announced strong second quarter financial results with total revenues of $932.9 million, a 24% increase compared to the same period in 2021, and affirmed its 2022 financial guidance.

Jazz Pharmaceuticals reported a strong first quarter in 2022, with total revenues of $813.7 million, a 34% increase compared to the same period in 2021. The company raised its top- and bottom-line guidance for 2022, driven by continued execution and significant progress across commercial and R&D.

Jazz Pharmaceuticals' total revenues reached $3.1 billion in 2021, a 31% increase compared to 2020, driven by growing commercial franchises and the acquisition of GW Pharmaceuticals. The company is focused on growing and diversifying revenue, investing in novel therapies, and delivering innovative therapies for patients. They expect meaningful top- and bottom-line growth with 2022 total revenue guidance of $3.46 to $3.66 billion.

Jazz Pharmaceuticals announced strong Q3 2021 results, with total revenues increasing by 39% to $838.1 million. The company also highlighted the successful integration of GW Pharmaceuticals and the launch of Xywav for idiopathic hypersomnia.

Jazz Pharmaceuticals announced a 34% increase in total revenues to $751.8 million compared to the second quarter of 2020. The company reaffirmed its 2021 total revenue guidance at $3.02 billion to $3.18 billion.

Jazz Pharmaceuticals reported a 14% increase in total revenues to $607.6 million compared to Q1 2020, driven by strong Xywav adoption and continued Zepzelca growth. The company affirmed its 2021 total revenue guidance of $2.55 billion to $2.70 billion and is on track to close the acquisition of GW Pharmaceuticals in early May.

Jazz Pharmaceuticals announced its Q4 2020 financial results, with total revenues increasing by 14% compared to the same period in 2019. The company highlighted the successful U.S. launches of Zepzelca and Xywav and provided full year 2021 total revenue guidance of $2.55 Billion to $2.70 Billion.

Jazz Pharmaceuticals reported a 12% increase in total revenues compared to the third quarter of 2019, driven by strong demand for Zepzelca and the launch of Xywav. The company also updated its 2020 financial guidance, increasing total revenue expectations to a range of $2.32 billion to $2.38 billion.

Jazz Pharmaceuticals announced strong Q2 2020 financial results, with total revenues increasing by 5% year-over-year. The company highlighted the FDA approval of Xywav and the launch of Zepzelca. The company also updated its 2020 financial guidance, increasing total revenue to a range of $2.225 billion to $2.325 billion and GAAP EPS to $3.40 - $4.85.

Jazz Pharmaceuticals announced its Q1 2020 financial results, reporting a 5% increase in total revenues to $535 million compared to the first quarter of 2019. The company is managing operating expenses and prioritizing investments in its most important current and future revenue drivers.

Jazz Pharmaceuticals announced its Q4 2019 financial results, reporting a 22% increase in total revenues compared to the same period in 2018. The company also highlighted key corporate and R&D updates, including the appointments of Renée Galá as CFO and Samantha Pearce as SVP, Europe/Rest of World.